Hepatitis C virus molecular evolution: Transmission, disease progression and antiviral therapy

World Journal of Gastroenterology

Volumn 20, Issue 43, 2014, Pages 15992-16013

  Preciado, Maria Victoria ^a   Valva, Pamela ^a   Escobar Gutierrez, Alejandro ^b   Rahal, Paula ^c   Ruiz Tovar, Karina ^b   Yamasaki, Lilian ^c   Vazquez Chacon, Carlos ^b   Martinez Guarneros, Armando ^b   Carpio Pedroza, Juan Carlos ^b   Fonseca Coronado, Salvador ^d   Cruz Rivera, Mayra ^e  

^a HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^b Instituto Nacional de Diagnostico y Referencia Epidemiologicos   (Mexico)

^c State University   (Brazil)

^d UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^e UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Clinical outcome; Drug resistance; Evolution; Hepatitis C virus; Phylogenetics

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NS3 PROTEASE INHIBITOR; NS5A INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; DISEASE COURSE; GENETIC HETEROGENEITY; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; MOLECULAR EVOLUTION; MOLECULAR PATHOLOGY; NONHUMAN; REVIEW; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS TRANSMISSION; ANIMAL; DRUG COMBINATION; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; HOST PATHOGEN INTERACTION; PATHOGENICITY; PHENOTYPE; TRANSMISSION; TREATMENT OUTCOME;

ANIMALS; ANTIVIRAL AGENTS; DISEASE PROGRESSION; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; EVOLUTION, MOLECULAR; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HOST-PATHOGEN INTERACTIONS; HUMANS; PHENOTYPE; TREATMENT OUTCOME;

EID: 84912523339     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i43.15992     Document Type: Review

References (256)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-1342 [PMID: 23172780 DOI: 10.1002/hep.26141].
2. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 2436-2441 [PMID: 17552026].
3. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29 Suppl 1: 74-81 [PMID: 19207969 DOI: 10.1111/j.1478-3231.2008.01934.x].
4. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52 [PMID: 11439948 DOI: 10.1056/NEJM200107053450107].
5. McHutchison JG, Bacon BR. Chronic hepatitis C: An age wave of disease burden. Am J Manag Care 2005; 11: S286-S295; quiz S307-S311 [PMID: 16232012].
6. Stanley ML, Walker C, Alter MJ, Yi M. Hepatitis C Virus In: Knipe DM, Howley PM, editors. Fields Virology. Philadelphia: Lippincott Williams & Wilkins, 2007: 1280.
7. Chevaliez S, Pawlotsky JM. HCV Genome and Life Cycle. In: Tan SL, editor. Hepatitis C Viruses: Genomes and Molecular Biology. UK: Norfolk, 2006.
8. Khaliq S, Jahan S, Pervaiz A. Sequence variability of HCV Core region: important predictors of HCV induced pathogenesis and viral production. Infect Genet Evol 2011; 11: 543-556 [PMID: 21292033 DOI: 10.1016/j.meegid.2011.01.017].
9. Drummer HE, Maerz A, Poumbourios P. Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins. FEBS Lett 2003; 546: 385-390 [PMID: 12832074].
10. Troesch M, Meunier I, Lapierre P, Lapointe N, Alvarez F, Boucher M, Soudeyns H. Study of a novel hypervariable region in hepatitis C virus (HCV) E2 envelope glycoprotein. Virology 2006; 352: 357-367 [PMID: 16781757 DOI: 10.1016/j.virol.2006.05.015].
11. Steinmann E, Penin F, Kallis S, Patel AH, Bartenschlager R, Pietschmann T. Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog 2007; 3: e103 [PMID: 17658949 DOI: 10.1371/journal.ppat.0030103].
12. Steinmann E, Pietschmann T. Hepatitis C virus p7- A viroporin crucial for virus assembly and an emerging target for antiviral therapy. Viruses 2010; 2: 2078-2095 [PMID: 21994720 DOI: 10.3390/v2092078].
13. Gallinari P, Brennan D, Nardi C, Brunetti M, Tomei L, Steinkühler C, De Francesco R. Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus. J Virol 1998; 72: 6758-6769 [PMID: 9658124].
14. Stapleford KA, Lindenbach BD. Hepatitis C virus NS2 coordinates virus particle assembly through physical interactions with the E1-E2 glycoprotein and NS3-NS4A enzyme complexes. J Virol 2011; 85: 1706-1717 [PMID: 21147927 DOI: 10.1128/JVI.02268-10].
15. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci USA 2005; 102: 17717-17722 [PMID: 16301520 DOI: 10.1073/pnas.0508531102].
16. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005; 437: 1167-1172 [PMID: 16177806 DOI: 10.1038/nature04193].
17. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, Ray SC, Gale M, Lemon SM. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 2005; 102: 2992-2997 [PMID: 15710891 DOI: 10.1073/pnas.0408824102].
18. Morikawa K, Lange CM, Gouttenoire J, Meylan E, Brass V, Penin F, Moradpour D. Nonstructural protein 3-4A: The Swiss army knife of hepatitis C virus. J Viral Hepat 2011; 18: 305-315 [PMID: 21470343 DOI: 10.1111/j.1365-2893.2011.01451.x].
19. Gouttenoire J, Penin F, Moradpour D. Hepatitis C virus nonstructural protein 4B: A journey into unexplored territory. Rev Med Virol 2010; 20: 117-129 [PMID: 20069613 DOI: 10.1002/rmv.640].
20. Macdonald A, Crowder K, Street A, McCormick C, Harris M. The hepatitis C virus NS5A protein binds to members of the Src family of tyrosine kinases and regulates kinase activity. J Gen Virol 2004; 85: 721-729 [PMID: 14993658].
21. Reed KE, Xu J, Rice CM. Phosphorylation of the hepatitis C virus NS5A protein in vitro and in vivo: properties of the NS5A- Associated kinase. J Virol 1997; 71: 7187-7197 [PMID: 9311791].
22. Behrens SE, Tomei L, De Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J 1996; 15: 12-22 [PMID: 8598194].
23. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-463 [PMID: 17487147 DOI: 10.1038/nrmicro1645].
24. Barth H, Schafer C, Adah MI, Zhang F, Linhardt RJ, Toyoda H, Kinoshita-Toyoda A, Toida T, Van Kuppevelt TH, Depla E, Von Weizsacker F, Blum HE, Baumert TF. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 2003; 278: 41003-41012 [PMID: 12867431 DOI: 10.1074/jbc.M302267200].
25. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, Vitelli A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002; 21: 5017-5025 [PMID: 12356718].
26. Hadlock KG, Lanford RE, Perkins S, Rowe J, Yang Q, Levy S, Pileri P, Abrignani S, Foung SK. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol 2000; 74: 10407-10416 [PMID: 11044085].
27. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S. Binding of hepatitis C virus to CD81. Science 1998; 282: 938-941 [PMID: 9794763].
28. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wölk B, Hatziioannou T, McKeating JA, Bieniasz PD, Rice CM. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007; 446: 801-805 [PMID: 17325668 DOI: 10.1038/nature05654].
29. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice CM. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009; 457: 882-886 [PMID: 19182773 DOI: 10.1038/nature07684].
30. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoël M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011; 17: 589-595 [PMID: 21516087 DOI: 10.1038/nm.2341].
31. Sainz B, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 2012; 18: 281-285 [PMID: 22231557 DOI: 10.1038/nm.2581].
32. Blanchard E, Belouzard S, Goueslain L, Wakita T, Dubuisson J, Wychowski C, Rouillé Y. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol 2006; 80: 6964-6972 [PMID: 16809302 DOI: 10.1128/JVI.00024-06].
33. Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, McKeating JA. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA 2003; 100: 7271-7276 [PMID: 12761383 DOI: 10.1073/pnas.0832180100].
34. Cruz-Rivera M, Carpio-Pedroza JC, Escobar-Gutiérrez A, Lozano D, Vergara-Castaneda A, Rivera-Osorio P, Martinez- Guarneros A, Chacon CA, Fonseca-Coronado S, Vaughan G. Rapid hepatitis C virus divergence among chronically infected individuals. J Clin Microbiol 2013; 51: 629-632 [PMID: 23224093 DOI: 10.1128/JCM.03042-12].
35. Honegger JR, Kim S, Price AA, Kohout JA, McKnight KL, Prasad MR, Lemon SM, Grakoui A, Walker CM. Loss of immune escape mutations during persistent HCV infection in pregnancy enhances replication of vertically transmitted viruses. Nat Med 2013; 19: 1529-1533 [PMID: 24162814 DOI: 10.1038/nm.3351].
36. von Hahn T, Yoon JC, Alter H, Rice CM, Rehermann B, Balfe P, McKeating JA. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007; 132: 667-678 [PMID: 17258731 DOI: 10.1053/j.gastro.2006.12.008].
37. Ralston R, Jacobson I, Scull M. The conundrum of relapse in STAT-C therapy: does HCV play the Red Queen or Rip Van Winkle? Semin Liver Dis 2011; 31: 410-419 [PMID: 22189980 DOI: 10.1055/s-0031-1297929].
38. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014; 59: 318-327 [PMID: 24115039 DOI: 10.1002/hep.26744].
39. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995; 15: 41-63 [PMID: 7597443 DOI: 10.1055/s-2007-1007262].
40. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, Beall E, Yap PL, Kolberg J, Urdea MS. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74 (Pt 11): 2391-2399 [PMID: 8245854].
41. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-115 [PMID: 21091831 DOI: 10.1111/j.1469-0691.2010.03432.x].
42. Agha S, Tanaka Y, Saudy N, Kurbanov F, Abo-Zeid M, El- Malky M, Khalaf M, Ohta N, Yoshizawa H, Mizokami M. Reliability of hepatitis C virus core antigen assay for detection of viremia in HCV genotypes 1, 2, 3, and 4 infected blood donors: A collaborative study between Japan, Egypt, and Uzbekistan. J Med Virol 2004; 73: 216-222 [PMID: 15122795 DOI: 10.1002/jmv.20078].
43. McOmish F, Yap PL, Dow BC, Follett EA, Seed C, Keller AJ, Cobain TJ, Krusius T, Kolho E, Naukkarinen R. Geographical distribution of hepatitis C virus genotypes in blood donors: An international collaborative survey. J Clin Microbiol 1994; 32: 884-892 [PMID: 7913097].
44. Kao JH, Chen PJ, Lai MY, Yang PM, Sheu JC, Wang TH, Chen DS. Genotypes of hepatitis C virus in Taiwan and the progression of liver disease. J Clin Gastroenterol 1995; 21: 233-237 [PMID: 8648060].
45. Simmonds P. The origin of hepatitis C virus. Curr Top Microbiol Immunol 2013; 369: 1-15 [PMID: 23463195 DOI: 10.1007/9 78-3-642-27340-7-1].
46. Magiorkinis G, Magiorkinis E, Paraskevis D, Ho SY, Shapiro B, Pybus OG, Allain JP, Hatzakis A. The global spread of hepatitis C virus 1a and 1b: A phylodynamic and phylogeographic analysis. PLoS Med 2009; 6: e1000198 [PMID: 20041120 DOI: 10.1371/journal.pmed.1000198].
47. Jackowiak P, Kuls K, Budzko L, Mania A, Figlerowicz M, Figlerowicz M. Phylogeny and molecular evolution of the hepatitis C virus. Infect Genet Evol 2014; 21: 67-82 [PMID: 24200590 DOI: 10.1016/j.meegid.2013.10.021].
48. Ribeiro RM, Li H, Wang S, Stoddard MB, Learn GH, Korber BT, Bhattacharya T, Guedj J, Parrish EH, Hahn BH, Shaw GM, Perelson AS. Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog 2012; 8: e1002881 [PMID: 22927817 DOI: 10.1371/journal.ppat.1002881].
49. Cuevas JM, González-Candelas F, Moya A, Sanjuán R. Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo. J Virol 2009; 83: 5760-5764 [PMID: 19321623 DOI: 10.1128/JVI.00201-09].
50. Lohmann V, Körner F, Dobierzewska A, Bartenschlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J Virol 2001; 75: 1437-1449 [PMID: 11152517 DOI: 10.1128/JVI.75.3.1437-1449.2001].
51. Campo DS, Dimitrova Z, Yokosawa J, Hoang D, Perez NO, Ramachandran S, Khudyakov Y. Hepatitis C virus antigenic convergence. Sci Rep 2012; 2: 267 [PMID: 22355779 DOI: 10.1038/srep00267].
52. Farci P. New insights into the HCV quasispecies and compartmentalization. Semin Liver Dis 2011; 31: 356-374 [PMID: 22189976 DOI: 10.1055/s-0031-1297925].
53. Penin F, Combet C, Germanidis G, Frainais PO, Deléage G, Pawlotsky JM. Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J Virol 2001; 75: 5703-5710 [PMID: 11356980 DOI: 10.1128/JVI.75.12.5703-5710.2001].
54. Quer J, Esteban JI, Cos J, Sauleda S, Ocaña L, Martell M, Otero T, Cubero M, Palou E, Murillo P, Esteban R, Guàrdia J. Effect of bottlenecking on evolution of the nonstructural protein 3 gene of hepatitis C virus during sexually transmitted acute resolving infection. J Virol 2005; 79: 15131-15141 [PMID: 16306585 DOI: 10.1128/JVI.79.24.15131-15141.2005].
55. Franco S, Parera M, Aparicio E, Clotet B, Martinez MA. Genetic and catalytic efficiency structure of an HCV protease quasispecies. Hepatology 2007; 45: 899-910 [PMID: 17393500 DOI: 10.1002/hep.21623].
56. Wang GP, Sherrill-Mix SA, Chang KM, Quince C, Bushman FD. Hepatitis C virus transmission bottlenecks analyzed by deep sequencing. J Virol 2010; 84: 6218-6228 [PMID: 20375170 DOI: 10.1128/JVI.02271-09].
57. Bull RA, Luciani F, McElroy K, Gaudieri S, Pham ST, Chopra A, Cameron B, Maher L, Dore GJ, White PA, Lloyd AR. Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection. PLoS Pathog 2011; 7: e1002243 [PMID: 21912520 DOI: 10.1371/journal.ppat.1002243].
58. D'Arienzo V, Moreau A, D'Alteroche L, Gissot V, Blanchard E, Gaudy-Graffin C, Roch E, Dubois F, Giraudeau B, Plantier JC, Goudeau A, Roingeard P, Brand D. Sequence and functional analysis of the envelope glycoproteins of hepatitis C virus variants selectively transmitted to a new host. J Virol 2013; 87: 13609-13618 [PMID: 24109215 DOI: 10.1128/JVI.02119-13].
59. Li H, Stoddard MB, Wang S, Blair LM, Giorgi EE, Parrish EH, Learn GH, Hraber P, Goepfert PA, Saag MS, Denny TN, Haynes BF, Hahn BH, Ribeiro RM, Perelson AS, Korber BT, Bhattacharya T, Shaw GM. Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. PLoS Pathog 2012; 8: e1002880 [PMID: 22927816 DOI: 10.1371/journal.ppat.1002880].
60. Kato N, Ootsuyama Y, Sekiya H, Ohkoshi S, Nakazawa T, Hijikata M, Shimotohno K. Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection. J Virol 1994; 68: 4776-4784 [PMID: 7518526].
61. van Doorn LJ, Quint W, Tsiquaye K, Voermans J, Paelinck D, Kos T, Maertens G, Schellekens H, Murray K. Longitudinal analysis of hepatitis C virus infection and genetic drift of the hypervariable region. J Infect Dis 1994; 169: 1226-1235 [PMID: 7545928].
62. Okamoto H, Kojima M, Okada S, Yoshizawa H, Iizuka H, Tanaka T, Muchmore EE, Peterson DA, Ito Y, Mishiro S. Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology 1992; 190: 894-899 [PMID: 1325713].
63. Allain JP, Dong Y, Vandamme AM, Moulton V, Salemi M. Evolutionary rate and genetic drift of hepatitis C virus are not correlated with the host immune response: Studies of infected donor-recipient clusters. J Virol 2000; 74: 2541-2549 [PMID: 10684268].
64. Kao JH, Chen PJ, Lai MY, Wang TH, Chen DS. Quasispecies of hepatitis C virus and genetic drift of the hypervariable region in chronic type C hepatitis. J Infect Dis 1995; 172: 261-264 [PMID: 7797927].
65. Worobey M, Holmes EC. Evolutionary aspects of recombination in RNA viruses. J Gen Virol 1999; 80 (Pt 10): 2535-2543 [PMID: 10573145].
66. Scheel TK, Galli A, Li YP, Mikkelsen LS, Gottwein JM, Bukh J. Productive homologous and non-homologous recombination of hepatitis C virus in cell culture. PLoS Pathog 2013; 9: e1003228 [PMID: 23555245 DOI: 10.1371/journal. ppat.1003228].
67. González-Candelas F, López-Labrador FX, Bracho MA. Recombination in hepatitis C virus. Viruses 2011; 3: 2006-2024 [PMID: 22069526 DOI: 10.3390/v3102006].
68. Shi W, Freitas IT, Zhu C, Zheng W, Hall WW, Higgins DG. Recombination in hepatitis C virus: identification of four novel naturally occurring inter-subtype recombinants. PLoS One 2012; 7: e41997 [PMID: 22911872 DOI: 10.1371/journal. pone.0041997].
69. Tscherne DM, Evans MJ, von Hahn T, Jones CT, Stamataki Z, McKeating JA, Lindenbach BD, Rice CM. Superinfection exclusion in cells infected with hepatitis C virus. J Virol 2007; 81: 3693-3703 [PMID: 17287280 DOI: 10.1128/JVI.01748-06].
70. Webster B, Ott M, Greene WC. Evasion of superinfection exclusion and elimination of primary viral RNA by an adapted strain of hepatitis C virus. J Virol 2013; 87: 13354-13369 [PMID: 24089557 DOI: 10.1128/JVI.02465-13].
71. Webster B, Wissing S, Herker E, Ott M, Greene WC. Rapid intracellular competition between hepatitis C viral genomes as a result of mitosis. J Virol 2013; 87: 581-596 [PMID: 23097449 DOI: 10.1128/JVI.01047-12].
72. Schaller T, Appel N, Koutsoudakis G, Kallis S, Lohmann V, Pietschmann T, Bartenschlager R. Analysis of hepatitis C virus superinfection exclusion by using novel fluorochrome gene-tagged viral genomes. J Virol 2007; 81: 4591-4603 [PMID: 17301154 DOI: 10.1128/JVI.02144-06].
73. Kalinina O, Norder H, Mukomolov S, Magnius LO. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J Virol 2002; 76: 4034-4043 [PMID: 11907242].
74. Sentandreu V, Jiménez-Hernández N, Torres-Puente M, Bracho MA, Valero A, Gosalbes MJ, Ortega E, Moya A, González-Candelas F. Evidence of recombination in intrapatient populations of hepatitis C virus. PLoS One 2008; 3: e3239 [PMID: 18800167 DOI: 10.1371/journal.pone.0003239].
75. Colina R, Casane D, Vasquez S, García-Aguirre L, Chunga A, Romero H, Khan B, Cristina J. Evidence of intratypic recombination in natural populations of hepatitis C virus. J Gen Virol 2004; 85: 31-37 [PMID: 14718617].
76. Kalinina O, Norder H, Magnius LO. Full-length open reading frame of a recombinant hepatitis C virus strain from St Petersburg: proposed mechanism for its formation. J Gen Virol 2004; 85: 1853-1857 [PMID: 15218169 DOI: 10.1099/vir.0.79984-0].
77. Wilke CO. Quasispecies theory in the context of population genetics. BMC Evol Biol 2005; 5: 44 [PMID: 16107214 DOI: 10.1186/1471-2148-5-44].
78. Holmes EC. The RNA virus quasispecies: fact or fiction? J Mol Biol 2010; 400: 271-273 [PMID: 20493194 DOI: 10.1016/j.jmb.2010.05.032].
79. Holmes EC. Does hepatitis C virus really form quasispecies? Infect Genet Evol 2010; 10: 431-432 [PMID: 20304103 DOI: 10.1016/j.meegid.2010.03.006].
80. Gismondi MI, Becker PD, Díaz Carrasco JM, Guzmán CA, Campos RH, Preciado MV. Evolution of hepatitis C virus hypervariable region 1 in immunocompetent children born to HCV-infected mothers. J Viral Hepat 2009; 16: 332-339 [PMID: 19228286].
81. Gismondi MI, Díaz Carrasco JM, Valva P, Becker PD, Guzmán CA, Campos RH, Preciado MV. Dynamic changes in viral population structure and compartmentalization during chronic hepatitis C virus infection in children. Virology 2013; 447: 187-196 [PMID: 24210114 DOI: 10.1016/j.virol.2013.09.002].
82. Ray SC, Fanning L, Wang XH, Netski DM, Kenny-Walsh E, Thomas DL. Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J Exp Med 2005; 201: 1753-1759 [PMID: 15939791 DOI: 10.1084/jem.20050122].
83. Escobar-Gutiérrez A, Soudeyns H, Larouche A, Carpio- Pedroza JC, Martinez-Guarneros A, Vazquez-Chacon CA, Fonseca-Coronado S, Yamasaki LH, Ruiz-Tovar K, Cruz- Rivera M. Vertical transmission of hepatitis C virus: A tale of multiple outcomes. Infect Genet Evol 2013; 20: 465-470 [PMID: 24140559 DOI: 10.1016/j.meegid.2013.10.005].
84. Larouche A, Gaëtan G, El-Bilali N, Quesnel-Vallières M, Martin SR, Alvarez F, Shoukry NH, Soudeyns H. Seronegative hepatitis C virus infection in a child infected via moth er-to-child transmission. J Clin Microbiol 2012; 50: 2515-2519 [PMID: 22535990 DOI: 10.1128/JCM.00622-12].
85. Ramachandran S, Campo DS, Dimitrova ZE, Xia GL, Purdy MA, Khudyakov YE. Temporal variations in the hepatitis C virus intrahost population during chronic infection. J Virol 2011; 85: 6369-6380 [PMID: 21525348 DOI: 10.1128/JVI.02204-10].
86. Gray RR, Salemi M, Klenerman P, Pybus OG. A new evolutionary model for hepatitis C virus chronic infection. PLoS Pathog 2012; 8: e1002656 [PMID: 22570609 DOI: 10.1371/journal.ppat.1002656].
87. Khudyakov Y. Molecular surveillance of hepatitis C. Antivir Ther 2012; 17: 1465-1470 [PMID: 23321496 DOI: 10.3851/IMP2476].
88. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, Schraut WW, Schirren CA, Waechtler M, Backmund M, Pape GR. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125: 80-88 [PMID: 12851873].
89. Shimizu YK, Igarashi H, Kanematu T, Fujiwara K, Wong DC, Purcell RH, Yoshikura H. Sequence analysis of the hepatitis C virus genome recovered from serum, liver, and peripheral blood mononuclear cells of infected chimpanzees. J Virol 1997; 71: 5769-5773 [PMID: 9223464].
90. Cabot B, Esteban JI, Martell M, Genescà J, Vargas V, Esteban R, Guardia J, Gómez J. Structure of replicating hepatitis C virus (HCV) quasispecies in the liver may not be reflected by analysis of circulating HCV virions. J Virol 1997; 71: 1732-1734 [PMID: 8995709].
91. Navas S, Martín J, Quiroga JA, Castillo I, Carreño V. Genetic diversity and tissue compartmentalization of the hepatitis C virus genome in blood mononuclear cells, liver, and serum from chronic hepatitis C patients. J Virol 1998; 72: 1640-1646 [PMID: 9445070].
92. Ducoulombier D, Roque-Afonso AM, Di Liberto G, Penin F, Kara R, Richard Y, Dussaix E, Féray C. Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes. Hepatology 2004; 39: 817-825 [PMID: 14999702 DOI: 10.1002/hep.20087].
93. Forton DM, Karayiannis P, Mahmud N, Taylor-Robinson SD, Thomas HC. Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. J Virol 2004; 78: 5170-5183 [PMID: 15113899].
94. Zignego AL, Giannini C, Monti M, Gragnani L. Hepatitis C virus lymphotropism: lessons from a decade of studies. Dig Liver Dis 2007; 39 Suppl 1: S38-S45 [PMID: 17936221].
95. Baré P. Hepatitis C virus and peripheral blood mononuclear cell reservoirs Patricia Baré. World J Hepatol 2009; 1: 67-71 [PMID: 21160967 DOI: 10.4254/wjh.v1.i1.67].
96. Bürgel B, Friesland M, Koch A, Manns MP, Wedemeyer H, Weissenborn K, Schulz-Schaeffer WJ, Pietschmann T, Steinmann E, Ciesek S. Hepatitis C virus enters human peripheral neuroblastoma cells - evidence for extra-hepatic cells sustaining hepatitis C virus penetration. J Viral Hepat 2011; 18: 562-570 [PMID: 20579278 DOI: 10.1111/j.1365-2893.2010.01339. x].
97. Blackard JT, Hiasa Y, Smeaton L, Jamieson DJ, Rodriguez I, Mayer KH, Chung RT. Compartmentalization of hepatitis C virus (HCV) during HCV/HIV coinfection. J Infect Dis 2007; 195: 1765-1773 [PMID: 17492592 DOI: 10.1086/518251].
98. Blackard JT, Kemmer N, Sherman KE. Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology 2006; 44: 15-22 [PMID: 16799966 DOI: 10.1002/hep.21283].
99. Sobesky R, Feray C, Rimlinger F, Derian N, Dos Santos A, Roque-Afonso AM, Samuel D, Bréchot C, Thiers V. Distinct hepatitis C virus core and F protein quasispecies in tumoral and nontumoral hepatocytes isolated via microdissection. Hepatology 2007; 46: 1704-1712 [PMID: 17935229 DOI: 10.1002/hep.21898].
100. Jouvencel AC, Neau D, Faure M, Neau M, Martinaud C, Legrand E, Trimoulet P, Garrigue I, Le Bail B, Bioulac-Sage P, Dupon M, Ragnaud JM, Fleury H, Lafon ME. Plasma and liver hepatitis C virus variability in patients coinfected with human immunodeficiency virus. J Clin Microbiol 2006; 44: 1877-1880 [PMID: 16672429 DOI: 10.1128/JCM.44.5.1877-1880.2006].
101. Vera-Otarola J, Barría MI, León U, Marsac D, Carvallo P, Soza A, López-Lastra M. Hepatitis C virus quasispecies in plasma and peripheral blood mononuclear cells of treatment naïve chronically infected patients. J Viral Hepat 2009; 16: 633-643 [PMID: 19254350 DOI: 10.1111/j.1365-2893.2009.01112.x].
102. Roque-Afonso AM, Ducoulombier D, Di Liberto G, Kara R, Gigou M, Dussaix E, Samuel D, Féray C. Compartmentalization of hepatitis C virus genotypes between plasma and peripheral blood mononuclear cells. J Virol 2005; 79: 6349-6357 [PMID: 15858018 DOI: 10.1128/JVI.79.10.6349-6357.2005].
103. Schramm F, Soulier E, Royer C, Weitten T, Fafi-Kremer S, Brignon N, Meyer N, Ellero B, Woehl-Jaegle ML, Meyer C, Wolf P, Doffoël M, Baumert TF, Stoll-Keller F, Schvoerer E. Frequent compartmentalization of hepatitis C virus with leukocyte-related amino acids in the setting of liver transplantation. J Infect Dis 2008; 198: 1656-1666 [PMID: 18925843 DOI: 10.1086/592986].
104. Laporte J, Bain C, Maurel P, Inchauspe G, Agut H, Cahour A. Differential distribution and internal translation efficiency of hepatitis C virus quasispecies present in dendritic and liver cells. Blood 2003; 101: 52-57 [PMID: 12393733 DOI: 10.1182/blood-2002-03-0818].
105. Pellerin M, Lopez-Aguirre Y, Penin F, Dhumeaux D, Pawlotsky JM. Hepatitis C virus quasispecies variability modulates nonstructural protein 5A transcriptional activation, pointing to cellular compartmentalization of virus-host interactions. J Virol 2004; 78: 4617-4627 [PMID: 15078944].
106. Blackard JT, Ma G, Welge JA, Martin CM, Sherman KE, Taylor LE, Mayer KH, Jamieson DJ. Analysis of a non-structural gene reveals evidence of possible hepatitis C virus (HCV) compartmentalization. J Med Virol 2012; 84: 242-252 [PMID: 22170544 DOI: 10.1002/jmv.22269].
107. Di Liberto G, Roque-Afonso AM, Kara R, Ducoulombier D, Fallot G, Samuel D, Feray C. Clinical and therapeutic implications of hepatitis C virus compartmentalization. Gastroenterology 2006; 131: 76-84 [PMID: 16831592 DOI: 10.1053/j.gastro.2006.04.016].
108. Welker MW, Welsch C, Ochs D, Hofmann WP, Herrmann E, Piiper A, Hartmann RW, Zeuzem S, Sarrazin C, Kronenberger B. Comparison of envelope 2 CD81 binding regions in PBMC-derived versus serum-derived hepatitis C virus isolates: higher conservation of CD81 region 2 in PBMC isolates. J Viral Hepat 2011; 18: 181-192 [PMID: 20367804 DOI: 10.1111/j.1365-2893.2010.01296.x].
109. Chen Z, Zhu Y, Ren Y, Tong Y, Hua X, Zhu F, Huang L, Liu Y, Luo Y, Lu W, Zhao P, Qi Z. Hepatitis C virus protects human B lymphocytes from Fas-mediated apoptosis via E2-CD81 engagement. PLoS One 2011; 6: e18933 [PMID: 21526201 DOI: 10.1371/journal.pone.0018933].
110. Sarhan MA, Pham TN, Chen AY, Michalak TI. Hepatitis C virus infection of human T lymphocytes is mediated by CD5. J Virol 2012; 86: 3723-3735 [PMID: 22278227 DOI: 10.1128/JVI.06956-11].
111. McGuinness PH, Bishop GA, McCaughan GW, Trowbridge R, Gowans EJ. False detection of negative-strand hepatitis C virus RNA. Lancet 1994; 343: 551-552 [PMID: 7509432].
112. Lanford RE, Chavez D, Chisari FV, Sureau C. Lack of detection of negative-strand hepatitis C virus RNA in peripheral blood mononuclear cells and other extrahepatic tissues by the highly strand-specific rTth reverse transcriptase PCR. J Virol 1995; 69: 8079-8083 [PMID: 7494326].
113. Laskus T, Radkowski M, Wang LF, Cianciara J, Vargas H, Rakela J. Hepatitis C virus negative strand RNA is not detected in peripheral blood mononuclear cells and viral sequences are identical to those in serum: A case against extrahepatic replication. J Gen Virol 1997; 78 (Pt 11): 2747-2750 [PMID: 9367359].
114. Armstrong GL. Commentary: Modelling the epidemiology of hepatitis C and its complications. Int J Epidemiol 2003; 32: 725-726 [PMID: 14559739].
115. Pawlotsky JM, Tsakiris L, Roudot-Thoraval F, Pellet C, Stuyver L, Duval J, Dhumeaux D. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. J Infect Dis 1995; 171: 1607-1610 [PMID: 7769300].
116. Pybus OG, Cochrane A, Holmes EC, Simmonds P. The hepatitis C virus epidemic among injecting drug users. Infect Genet Evol 2005; 5: 131-139 [PMID: 15639745 DOI: 10.1016/j.meegid.2004.08.001].
117. Pybus OG, Charleston MA, Gupta S, Rambaut A, Holmes EC, Harvey PH. The epidemic behavior of the hepatitis C virus. Science 2001; 292: 2323-2325 [PMID: 11423661 DOI: 10.1126/science. 1058321].
118. Thomson BJ, Finch RG. Hepatitis C virus infection. Clin Microbiol Infect 2005; 11: 86-94 [PMID: 15679481 DOI: 10.1111/j.1469-0691.2004.01061.x].
119. Escobar-Gutiérrez A, Vazquez-Pichardo M, Cruz-Rivera M, Rivera-Osorio P, Carpio-Pedroza JC, Ruíz-Pacheco JA, Ruiz- Tovar K, Vaughan G. Identification of hepatitis C virus transmission using a next-generation sequencing approach. J Clin Microbiol 2012; 50: 1461-1463 [PMID: 22301026 DOI: 10.1128/JCM.00005-12].
120. Williams IT, Bell BP, Kuhnert W, Alter MJ. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch Intern Med 2011; 171: 242-248 [PMID: 21325115 DOI: 10.1001/archinternmed.2010.511].
121. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47: 1-39 [PMID: 9790221].
122. Araujo AC. Antibody- And genome-based identification of recent HCV infection. Antivir Ther 2012; 17: 1459-1464 [PMID: 23322615 DOI: 10.3851/IMP2464].
123. Abecasis AB, Geretti AM, Albert J, Power L, Weait M, Vandamme AM. Science in court: The myth of HIV fingerprinting. Lancet Infect Dis 2011; 11: 78-79 [PMID: 21272786 DOI: 10.1016/S1473-3099(10)70283-8].
124. Vandamme AM, Pybus OG. Viral phylogeny in court: The unusual case of the Valencian anesthetist. BMC Biol 2013; 11: 83 [PMID: 24059471 DOI: 10.1186/1741-7007-11-83].
125. González-Candelas F, Bracho MA, Wróbel B, Moya A. Molecular evolution in court: Analysis of a large hepatitis C virus outbreak from an evolving source. BMC Biol 2013; 11: 76 [PMID: 23870105 DOI: 10.1186/1741-7007-11-76].
126. Wróbel B, Torres-Puente M, Jiménez N, Bracho MA, García- Robles I, Moya A, González-Candelas F. Analysis of the overdispersed clock in the short-term evolution of hepatitis C virus: Using the E1/E2 gene sequences to infer infection dates in a single source outbreak. Mol Biol Evol 2006; 23: 1242-1253 [PMID: 16585120 DOI: 10.1093/molbev/msk012].
127. de Oliveira T, Pybus OG, Rambaut A, Salemi M, Cassol S, Ciccozzi M, Rezza G, Gattinara GC, D'Arrigo R, Amicosante M, Perrin L, Colizzi V, Perno CF. Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak. Nature 2006; 444: 836-837 [PMID: 17171825].
128. Indolfi G, Azzari C, Resti M. Hepatitis: Immunoregulation in pregnancy and perinatal transmission of HCV. Nat Rev Gastroenterol Hepatol 2014; 11: 6-7 [PMID: 24296582 DOI: 10.1038/nrgastro.2013.230].
129. Indolfi G, Azzari C, Resti M. Perinatal transmission of hepatitis C virus. J Pediatr 2013; 163: 1549-1552.e1 [PMID: 23919905 DOI: 10.1016/j.jpeds.2013.06.077].
130. Azzari C, Moriondo M, Indolfi G, Betti L, Gambineri E, de Martino M, Resti M. Higher risk of hepatitis C virus perinatal transmission from drug user mothers is mediated by peripheral blood mononuclear cell infection. J Med Virol 2008; 80: 65-71 [PMID: 18041020 DOI: 10.1002/jmv.21023].
131. Azzari C, Resti M, Moriondo M, Ferrari R, Lionetti P, Vierucci A. Vertical transmission of HCV is related to maternal peripheral blood mononuclear cell infection. Blood 2000; 96: 2045-2048 [PMID: 10979945].
132. Kudo T, Yanase Y, Ohshiro M, Yamamoto M, Morita M, Shibata M, Morishima T. Analysis of mother-to-infant transmission of hepatitis C virus: quasispecies nature and buoyant densities of maternal virus populations. J Med Virol 1997; 51: 225-230 [PMID: 9139088].
133. Fonseca-Coronado S, Escobar-Gutiérrez A, Ruiz-Tovar K, Cruz-Rivera MY, Rivera-Osorio P, Vazquez-Pichardo M, Carpio-Pedroza JC, Ruíz-Pacheco JA, Cazares F, Vaughan G. Specific detection of naturally occurring hepatitis C virus mutants with resistance to telaprevir and boceprevir (protease inhibitors) among treatment-naïve infected individuals. J Clin Microbiol 2012; 50: 281-287 [PMID: 22116161 DOI: 10.1128/JCM.05842-11].
134. Fonseca-Coronado S, Vaughan G, Cruz-Rivera MY, Carpio- Pedroza JC, Ruiz-Tovar K, Ruiz-Pacheco JA, Escobar- Gutiérrez A. Interleukin-28B genotyping by melt-mismatch amplification mutation assay PCR analysis using single nucleotide polymorphisms rs12979860 and rs8099917, a useful tool for prediction of therapy response in hepatitis C patients. J Clin Microbiol 2011; 49: 2706-2710 [PMID: 21613433 DOI: 10.1128/JCM.00877-11].
135. Ramachandran S, Xia GL, Ganova-Raeva LM, Nainan OV, Khudyakov Y. End-point limiting-dilution real-time PCR assay for evaluation of hepatitis C virus quasispecies in serum: performance under optimal and suboptimal conditions. J Virol Methods 2008; 151: 217-224 [PMID: 18571738 DOI: 10.1016/j.jviromet.2008.05.005].
136. Cruz-Rivera M, Forbi JC, Yamasaki LH, Vazquez-Chacon CA, Martinez-Guarneros A, Carpio-Pedroza JC, Escobar- Gutiérrez A, Ruiz-Tovar K, Fonseca-Coronado S, Vaughan G. Molecular epidemiology of viral diseases in the era of next generation sequencing. J Clin Virol 2013; 57: 378-380 [PMID: 23726419 DOI: 10.1016/j.jcv.2013.04.021].
137. Forbi JC, Purdy MA, Campo DS, Vaughan G, Dimitrova ZE, Ganova-Raeva LM, Xia GL, Khudyakov YE. Epidemic history of hepatitis C virus infection in two remote communities in Nigeria, West Africa. J Gen Virol 2012; 93: 1410-1421 [PMID: 22456613 DOI: 10.1099/vir.0.042184-0].
138. Miura M, Maekawa S, Takano S, Komatsu N, Tatsumi A, Asakawa Y, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. Deepsequencing analysis of the association between the quasispecies nature of the hepatitis C virus core region and disease progression. J Virol 2013; 87: 12541-12551 [PMID: 23946458 DOI: 10.1128/JVI.00826-13].
139. Lauck M, Alvarado-Mora MV, Becker EA, Bhattacharya D, Striker R, Hughes AL, Carrilho FJ, O'Connor DH, Pinho JR. Analysis of hepatitis C virus intrahost diversity across the coding region by ultradeep pyrosequencing. J Virol 2012; 86: 3952-3960 [PMID: 22278255 DOI: 10.1128/JVI.06627-11].
140. Beerenwinkel N, Günthard HF, Roth V, Metzner KJ. Challenges and opportunities in estimating viral genetic diversity from next-generation sequencing data. Front Microbiol 2012; 3: 329 [PMID: 22973268 DOI: 10.3389/fmicb.2012.00329].
141. Caraballo Cortés K, Zagordi O, Laskus T, Płoski R, Bukowska-Osko I, Pawełczyk A, Berak H, Radkowski M. Ultradeep pyrosequencing of hepatitis C virus hypervariable region 1 in quasispecies analysis. Biomed Res Int 2013; 2013: 626083 [PMID: 23710455 DOI: 10.1155/2013/626083].
142. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, Chien DY, Munoz SJ, Balestrieri A, Purcell RH, Alter HJ. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288: 339-344 [PMID: 10764648].
143. Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, Coiana A, Peddis G, Usai F, Serra G, Chessa L, Diaz G, Balestrieri A, Purcell RH. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci USA 2002; 99: 3081-3086 [PMID: 11880647 DOI: 10.1073/pnas.052712599].
144. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hürter D, Nawrocki M, Kruska L, Hensel F, Petry W, Häussinger D. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687-1695 [PMID: 9828236 DOI: 10.1002/hep.510280632].
145. Ripoli M, Pazienza V. Impact of HCV genetic differences on pathobiology of disease. Expert Rev Anti Infect Ther 2011; 9: 747-759 [PMID: 21905784 DOI: 10.1586/eri.11.94].
146. Amoroso P, Rapicetta M, Tosti ME, Mele A, Spada E, Buonocore S, Lettieri G, Pierri P, Chionne P, Ciccaglione AR, Sagliocca L. Correlation between virus genotype and chronicity rate in acute hepatitis C. J Hepatol 1998; 28: 939-944 [PMID: 9672167 DOI: 10.1016/S0168-8278(98)80340-1].
147. Bantel H, Lügering A, Poremba C, Lügering N, Held J, Domschke W, Schulze-Osthoff K. Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology 2001; 34: 758-767 [PMID: 11584373 DOI: 10.1053/jhep.2001.28229].
148. Aweya JJ, Tan YJ. Modulation of programmed cell death pathways by the hepatitis C virus. Front Biosci (Landmark Ed) 2011; 16: 608-618 [PMID: 21196192].
149. Malhi H, Gores GJ. Cellular and molecular mechanisms of liver injury. Gastroenterology 2008; 134: 1641-1654 [PMID: 18471544 DOI: 10.1053/j.gastro.2008.03.002].
150. Shiu TY, Huang SM, Shih YL, Chu HC, Chang WK, Hsieh TY. Hepatitis C virus core protein down-regulates p21(Waf1/Cip1) and inhibits curcumin-induced apoptosis through microRNA-345 targeting in human hepatoma cells. PLoS One 2013; 8: e61089 [PMID: 23577194 DOI: 10.1371/journal. pone.0061089].
151. Jahan S, Khaliq S, Siddiqi MH, Ijaz B, Ahmad W, Ashfaq UA, Hassan S. Anti- Apoptotic effect of HCV core gene of genotype 3a in Huh-7 cell line. Virol J 2011; 8: 522 [PMID: 22108100 DOI: 10.1186/1743-422X-8-522].
152. Nakamura H, Aoki H, Hino O, Moriyama M. HCV core protein promotes heparin binding EGF-like growth factor expression and activates Akt. Hepatol Res 2011; 41: 455-462 [PMID: 21418450 DOI: 10.1111/j.1872-034X.2011.00792.x].
153. Berg CP, Schlosser SF, Neukirchen DK, Papadakis C, Gregor M, Wesselborg S, Stein GM. Hepatitis C virus core protein induces apoptosis-like caspase independent cell death. Virol J 2009; 6: 213 [PMID: 19951438 DOI: 10.1186/1743-422X-6-213].
154. Siavoshian S, Abraham JD, Thumann C, Kieny MP, Schuster C. Hepatitis C virus core, NS3, NS5A, NS5B proteins induce apoptosis in mature dendritic cells. J Med Virol 2005; 75: 402-411 [PMID: 15648076 DOI: 10.1002/jmv.20283].
155. Machida K, Tsukiyama-Kohara K, Seike E, Toné S, Shibasaki F, Shimizu M, Takahashi H, Hayashi Y, Funata N, Taya C, Yonekawa H, Kohara M. Inhibition of cytochrome c release in Fas-mediated signaling pathway in transgenic mice induced to express hepatitis C viral proteins. J Biol Chem 2001; 276: 12140-12146 [PMID: 11278624 DOI: 10.1074/jbc. M010137200].
156. Saito K, Meyer K, Warner R, Basu A, Ray RB, Ray R. Hepatitis C virus core protein inhibits tumor necrosis factor alphamediated apoptosis by a protective effect involving cellular FLICE inhibitory protein. J Virol 2006; 80: 4372-4379 [PMID: 16611896 DOI: 10.1128/JVI.80.9.4372-4379.2006].
157. Kao CF, Chen SY, Chen JY, Wu Lee YH. Modulation of p53 transcription regulatory activity and post-translational modification by hepatitis C virus core protein. Oncogene 2004; 23: 2472-2483 [PMID: 14968111 DOI: 10.1038/sj.onc.1207368].
158. Otsuka M, Kato N, Lan K, Yoshida H, Kato J, Goto T, Shiratori Y, Omata M. Hepatitis C virus core protein enhances p53 function through augmentation of DNA binding affinity and transcriptional ability. J Biol Chem 2000; 275: 34122-34130 [PMID: 10924497 DOI: 10.1074/jbc.M000578200].
159. Koike K. Molecular basis of hepatitis C virus- Associated hepatocarcinogenesis: lessons from animal model studies. Clin Gastroenterol Hepatol 2005; 3: S132-S135 [PMID: 16234061].
160. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy. J Med Virol 2011; 83: 1016-1022 [PMID: 21503914 DOI: 10.1002/jmv.22094].
161. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology 2007; 46: 1357-1364 [PMID: 17657816 DOI: 10.1002/hep.21836].
162. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma. J Med Virol 2008; 80: 1354-1362 [PMID: 18551609 DOI: 10.1002/jmv.21202].
163. Fishman SL, Factor SH, Balestrieri C, Fan X, Dibisceglie AM, Desai SM, Benson G, Branch AD. Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma. Clin Cancer Res 2009; 15: 3205-3213 [PMID: 19383824 DOI: 10.1158/1078-0432.CCR-08-2418].
164. Rüster B, Zeuzem S, Krump-Konvalinkova V, Berg T, Jonas S, Severin K, Roth WK. Comparative sequence analysis of the core- And NS5-region of hepatitis C virus from tumor and adjacent non-tumor tissue. J Med Virol 2001; 63: 128-134 [PMID: 11170049].
165. Alam SS, Nakamura T, Naganuma A, Nozaki A, Nouso K, Shimomura H, Kato N. Hepatitis C virus quasispecies in cancerous and noncancerous hepatic lesions: The core protein- encoding region. Acta Med Okayama 2002; 56: 141-147 [PMID: 12108585].
166. De Mitri MS, Mele L, Chen CH, Piccinini A, Chianese R, D' Errico A, Alberti A, Pisi E. Comparison of serum and liver hepatitis C virus quasispecies in HCV-related hepatocellular carcinoma. J Hepatol 1998; 29: 887-892 [PMID: 9875634].
167. Horie C, Iwahana H, Horie T, Shimizu I, Yoshimoto K, Yogita S, Tashiro S, Ito S, Itakura M. Detection of different quasispecies of hepatitis C virus core region in cancerous and noncancerous lesions. Biochem Biophys Res Commun 1996; 218: 674-681 [PMID: 8579573 DOI: 10.1006/bbrc.1996.0121].
168. Ogata S, Nagano-Fujii M, Ku Y, Yoon S, Hotta H. Comparative sequence analysis of the core protein and its frameshift product, the F protein, of hepatitis C virus subtype 1b strains obtained from patients with and without hepatocellular carcinoma. J Clin Microbiol 2002; 40: 3625-3630 [PMID: 12354856].
169. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994; 21: 1135-1139 [PMID: 7699240].
170. Antonelli A, Ferri C, Fallahi P, Pampana A, Ferrari SM, Goglia F, Ferrannini E. Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care 2005; 28: 2548-2550 [PMID: 16186298].
171. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus. J Med Virol 2009; 81: 1032-1039 [PMID: 19382270 DOI: 10.1002/jmv.21473].
172. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364 [PMID: 11391523 DOI: 10.1053/jhep.2001.24432].
173. Rubbia-Brandt L, Leandro G, Spahr L, Giostra E, Quadri R, Malé PJ, Negro F. Liver steatosis in chronic hepatitis C: A morphological sign suggesting infection with HCV genotype 3. Histopathology 2001; 39: 119-124 [PMID: 11493327].
174. Tachi Y, Katano Y, Honda T, Hayashi K, Ishigami M, Itoh A, Hirooka Y, Nakano I, Samejima Y, Goto H. Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C. Liver Int 2010; 30: 554-559 [PMID: 19951380 DOI: 10.1111/j.1478-3231.2009.02164.x].
175. Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, Müllhaupt B, Borovicka J, Heim M, Moradpour D, Cerny A, Malinverni R, Francioli P, Negro F. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51: 655-666 [PMID: 19665246 DOI: 10.1016/j.jhep.2009.05.016].
176. De Mitri MS, Cassini R, Bagaglio S, Morsica G, Andreone P, Marino N, Bernardi M. Evolution of hepatitis C virus nonstructural 5A gene in the progression of liver disease to hepatocellular carcinoma. Liver Int 2007; 27: 1126-1133 [PMID: 17845542 DOI: 10.1111/j.1478-3231.2007.01537.x].
177. Ghosh AK, Majumder M, Steele R, Meyer K, Ray R, Ray RB. Hepatitis C virus NS5A protein protects against TNF- Alpha mediated apoptotic cell death. Virus Res 2000; 67: 173-178 [PMID: 10867196].
178. Ghosh AK, Steele R, Meyer K, Ray R, Ray RB. Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. J Gen Virol 1999; 80 (Pt 5): 1179-1183 [PMID: 10355764].
179. Gale M, Blakely CM, Kwieciszewski B, Tan SL, Dossett M, Tang NM, Korth MJ, Polyak SJ, Gretch DR, Katze MG. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998; 18: 5208-5218 [PMID: 9710605].
180. Chung KM, Song OK, Jang SK. Hepatitis C virus nonstructural protein 5A contains potential transcriptional activator domains. Mol Cells 1997; 7: 661-667 [PMID: 9387155].
181. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81 [PMID: 8531962 DOI: 10.1056/NEJM199601113340203].
182. Qin H, Shire NJ, Keenan ED, Rouster SD, Eyster ME, Goedert JJ, Koziel MJ, Sherman KE. HCV quasispecies evolution: Association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV. Blood 2005; 105: 533-541 [PMID: 15374882 DOI: 10.1182/blood-2004-04-1452].
183. Canobio S, Guilbert CM, Troesch M, Samson J, Lemay M, Pelletier VA, Bernard-Bonnin AC, Kozielski R, Lapointe N, Martin SR, Soudeyns H. Differing patterns of liver disease progression and hepatitis C virus (HCV) quasispecies evolution in children vertically coinfected with HCV and human immunodeficiency virus type 1. J Clin Microbiol 2004; 42: 4365-4369 [PMID: 15365046 DOI: 10.1128/JCM.42.9.4365-4369.2004].
184. Arenas JI, Gallegos-Orozco JF, Laskus T, Wilkinson J, Khatib A, Fasola C, Adair D, Radkowski M, Kibler KV, Nowicki M, Douglas D, Williams J, Netto G, Mulligan D, Klintmalm G, Rakela J, Vargas HE. Hepatitis C virus quasi-species dynamics predict progression of fibrosis after liver transplantation. J Infect Dis 2004; 189: 2037-2046 [PMID: 15143471 DOI: 10.1086/386338].
185. Martell M, Esteban JI, Quer J, Vargas V, Esteban R, Guardia J, Gómez J. Dynamic behavior of hepatitis C virus quasispecies in patients undergoing orthotopic liver transplantation. J Virol 1994; 68: 3425-3436 [PMID: 8151804].
186. Gretch DR, Polyak SJ, Wilson JJ, Carithers RL, Perkins JD, Corey L. Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients. J Virol 1996; 70: 7622-7631 [PMID: 8892882].
187. Pessoa MG, Bzowej N, Berenguer M, Phung Y, Kim M, Ferrell L, Hassoba H, Wright TL. Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. Hepatology 1999; 30: 1513-1520 [PMID: 10573532 DOI: 10.1002/hep.510300610].
188. Chopra KB, Demetris AJ, Blakolmer K, Dvorchik I, Laskus T, Wang LF, Araya VR, Dodson F, Fung JJ, Rakela J, Vargas HE. Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation. Transplantation 2003; 76: 1487-1491 [PMID: 14657691 DOI: 10.1097/01. TP.0000088668.28950.7C].
189. Araya V, Rakela J, Wright T. Hepatitis C after orthotopic liver transplantation. Gastroenterology 1997; 112: 575-582 [PMID: 9024312].
190. Vargas HE, Laskus T, Wang LF, Radkowski M, Poutous A, Lee R, Demetris JA, Gayowski T, Marino IR, Singh N, Dodson F, Casavilla A, Fung JJ, Rakela J. The influence of hepatitis C virus genotypes on the outcome of liver transplantation. Liver Transpl Surg 1998; 4: 22-27 [PMID: 9457963].
191. Féray C, Gigou M, Samuel D, Paradis V, Mishiro S, Maertens G, Reynés M, Okamoto H, Bismuth H, Bréchot C. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995; 108: 1088-1096 [PMID: 7698576].
192. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, Detre K, Hoofnagle J. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823-830 [PMID: 9731579 DOI: 10.1002/hep.510280333].
193. Burak KW, Kremers WK, Batts KP, Wiesner RH, Rosen CB, Razonable RR, Paya CV, Charlton MR. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8: 362-369 [PMID: 11965581 DOI: 10.1053/jlts.2002.32282].
194. Rosen HR, Chou S, Corless CL, Gretch DR, Flora KD, Boudousquie A, Orloff SL, Rabkin JM, Benner KG. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 1997; 64: 721-726 [PMID: 9311709].
195. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492-497 [PMID: 11170959 DOI: 10.1086/318501].
196. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, Sarrazin C, Harvey J, Brass C, Albrecht J. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993-999 [PMID: 15158341 DOI: 10.1016/j.jhep.2004.02.007].
197. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401 [PMID: 19684573 DOI: 10.1038/nature08309].
198. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007; 46: 1688-1694 [PMID: 18046717 DOI: 10.1002/hep.21919].
199. Webster G, Barnes E, Brown D, Dusheiko G. HCV genotypes- -role in pathogenesis of disease and response to therapy. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 229-240 [PMID: 10890318].
200. Shen C, Hu T, Shen L, Gao L, Xie W, Zhang J. Mutations in ISDR of NS5A gene influence interferon efficacy in Chinese patients with chronic hepatitis C virus genotype 1b infection. J Gastroenterol Hepatol 2007; 22: 1898-1903 [PMID: 17914967 DOI: 10.1111/j.1440-1746.2006.04566.x].
201. Murakami T, Enomoto N, Kurosaki M, Izumi N, Marumo F, Sato C. Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection. Hepatology 1999; 30: 1045-1053 [PMID: 10498658 DOI: 10.1002/hep.510300405].
202. Zeuzem S, Lee JH, Roth WK. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology 1997; 25: 740-744 [PMID: 9049228 DOI: 10.1002/hep.510250341].
203. Murphy MD, Rosen HR, Marousek GI, Chou S. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon- Alpha and ribavirin therapy in chronic hepatitis C infection. Dig Dis Sci 2002; 47: 1195-1205 [PMID: 12064791].
204. Ilyas JA, Vierling JM. An overview of emerging therapies for the treatment of chronic hepatitis C. Med Clin North Am 2014; 98: 17-38 [PMID: 24266912 DOI: 10.1016/j.mcna.2013.10.011].
205. Ploss A, Dubuisson J. New advances in the molecular biology of hepatitis C virus infection: Towards the identification of new treatment targets. Gut 2012; 61 Suppl 1: i25-i35 [PMID: 22504917 DOI: 10.1136/gutjnl-2012-302048].
206. Delang L, Neyts J, Vliegen I, Abrignani S, Neddermann P, De Francesco R. Hepatitis C virus-specific directly acting antiviral drugs. Curr Top Microbiol Immunol 2013; 369: 289-320 [PMID: 23463206 DOI: 10.1007/978-3-642-27340-7-12].
207. Bartenschlager R. Hepatitis C Virus: From Molecular Virology to Antiviral Therapy (Current Topics in Microbiology and Immunology). 2013th. Publisher: Springer, 2013; 369.
208. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217 [PMID: 21449784 DOI: 10.1056/NEJMoa1009482].
209. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, Di- Nubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206 [PMID: 21449783 DOI: 10.1056/NEJMoa1010494].
210. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428 [PMID: 21696308 DOI: 10.1056/NEJMoa1013086].
211. Welsch C, Jesudian A, Zeuzem S, Jacobson I. New directacting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 2012; 61 Suppl 1: i36-i46 [PMID: 22504918 DOI: 10.1136/gutjnl-2012-302144].
212. Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, Poynard T, Samuel D, Bourlière M, Zarski JP, Raabe JJ, Alric L, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Métivier S, Tran A, Serfaty L, Abergel A, Causse X, Di Martino V, Guyader D, Lucidarme D, Grando-Lemaire V, Hillon P, Feray C, Dao T, Cacoub P, Rosa I, Attali P, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP. Triple therapy in treatmentexperienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20- CUPIC) - NCT01514890. J Hepatol 2013; 59: 434-441 [PMID: 23669289 DOI: 10.1016/j.jhep.2013.04.035].
213. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995; 69: 5087-5094 [PMID: 7541846].
214. Lu L, Dekhtyar T, Masse S, Pithawalla R, Krishnan P, He W, Ng T, Koev G, Stewart K, Larson D, Bosse T, Wagner R, Pilot-Matias T, Mo H, Molla A. Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro. Antiviral Res 2007; 76: 93-97 [PMID: 17561278 DOI: 10.1016/j.antiviral.2007.04.005].
215. Cubero M, Esteban JI, Otero T, Sauleda S, Bes M, Esteban R, Guardia J, Quer J. Naturally occurring NS3-proteaseinhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology 2008; 370: 237-245 [PMID: 18006035 DOI: 10.1016/j.virol.2007.10.006].
216. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, Heckerman D, Carlson J, Reyor LL, Kleyman M, McMahon CM, Birch C, Schulze Zur Wiesch J, Ledlie T, Koehrsen M, Kodira C, Roberts AD, Lauer GM, Rosen HR, Bihl F, Cerny A, Spengler U, Liu Z, Kim AY, Xing Y, Schneidewind A, Madey MA, Fleckenstein JF, Park VM, Galagan JE, Nusbaum C, Walker BD, Lake-Bakaar GV, Daar ES, Jacobson IM, Gomperts ED, Edlin BR, Donfield SM, Chung RT, Talal AH, Marion T, Birren BW, Henn MR, Allen TM. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology 2008; 48: 1769-1778 [PMID: 19026009 DOI: 10.1002/hep.22549].
217. Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, Kwong AD, Zeuzem S. Telaprevir and pegylated interferon- Alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46: 631-639 [PMID: 17680654 DOI: 10.1002/hep.21781].
218. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138: 447-462 [PMID: 20006612 DOI: 10.1053/j.gastro.2009.11.055].
219. Zeminian LB, Padovani JL, Corvino SM, Silva GF, Pardini MI, Grotto RM. Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors. Mem Inst Oswaldo Cruz 2013; 108: 13-17 [PMID: 23440108].
220. Wyles DL. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J Infect Dis 2013; 207 Suppl 1: S33-S39 [PMID: 23390303 DOI: 10.1093/infdis/jis761].
221. Susser S, Vermehren J, Forestier N, Welker MW, Grigorian N, Füller C, Perner D, Zeuzem S, Sarrazin C. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin Virol 2011; 52: 321-327 [PMID: 21924672 DOI: 10.1016/j.jcv.2011.08.015].
222. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011; 55: 192-206 [PMID: 21284949 DOI: 10.1016/j.jhep.2011.01.011].
223. Manns MP, von Hahn T. Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov 2013; 12: 595-610 [PMID: 23807378 DOI: 10.1038/nrd4050].
224. Shah N, Pierce T, Kowdley KV. Review of direct- Acting antiviral agents for the treatment of chronic hepatitis C. Expert Opin Investig Drugs 2013; 22: 1107-1121 [PMID: 23735127 DOI: 10.1517/13543784.2013.806482].
225. McCown MF, Rajyaguru S, Kular S, Cammack N, Nájera I. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother 2009; 53: 2129-2132 [PMID: 19273674 DOI: 10.1128/AAC.01598-08].
226. Ciesek S, von Hahn T, Manns MP. Second-wave protease inhibitors: choosing an heir. Clin Liver Dis 2011; 15: 597-609 [PMID: 21867939 DOI: 10.1016/j.cld.2011.05.014].
227. White PW, Llinàs-Brunet M, Amad M, Bethell RC, Bolger G, Cordingley MG, Duan J, Garneau M, Lagacé L, Thibeault D, Kukolj G. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob Agents Chemother 2010; 54: 4611-4618 [PMID: 20823284 DOI: 10.1128/AAC.00787-10].
228. Lin TI, Lenz O, Fanning G, Verbinnen T, Delouvroy F, Scholliers A, Vermeiren K, Rosenquist A, Edlund M, Samuelsson B, Vrang L, de Kock H, Wigerinck P, Raboisson P, Simmen K. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother 2009; 53: 1377-1385 [PMID: 19171797 DOI: 10.1128/AAC.01058-08].
229. Seiwert SD, Andrews SW, Jiang Y, Serebryany V, Tan H, Kossen K, Rajagopalan PT, Misialek S, Stevens SK, Stoycheva A, Hong J, Lim SR, Qin X, Rieger R, Condroski KR, Zhang H, Do MG, Lemieux C, Hingorani GP, Hartley DP, Josey JA, Pan L, Beigelman L, Blatt LM. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother 2008; 52: 4432-4441 [PMID: 18824605 DOI: 10.1128/AAC.00699-08].
230. Sheng XC, Appleby T, Butler T, Cai R, Chen X, Cho A, Clarke MO, Cottell J, Delaney WE, Doerffler E, Link J, Ji M, Pakdaman R, Pyun HJ, Wu Q, Xu J, Kim CU. Discovery of GS-9451: An acid inhibitor of the hepatitis C virus NS3/4A protease. Bioorg Med Chem Lett 2012; 22: 2629-2634 [PMID: 22366653 DOI: 10.1016/j.bmcl.2012.01.017].
231. Sheng XC, Casarez A, Cai R, Clarke MO, Chen X, Cho A, Delaney WE, Doerffler E, Ji M, Mertzman M, Pakdaman R, Pyun HJ, Rowe T, Wu Q, Xu J, Kim CU. Discovery of GS-9256: A novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. Bioorg Med Chem Lett 2012; 22: 1394-1396 [PMID: 22244938 DOI: 10.1016/j.bmcl.2011.12.038].
232. Agarwal A, Zhang B, Olek E, Robison H, Robarge L, Deshpande M. Rapid and sharp decline in HCV upon monotherapy with NS3 protease inhibitor, ACH-1625. Antivir Ther 2012; 17: 1533-1539 [PMID: 22976492 DOI: 10.3851/IMP2359].
233. McPhee F, Sheaffer AK, Friborg J, Hernandez D, Falk P, Zhai G, Levine S, Chaniewski S, Yu F, Barry D, Chen C, Lee MS, Mosure K, Sun LQ, Sinz M, Meanwell NA, Colonno RJ, Knipe J, Scola P. Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). Antimicrob Agents Chemother 2012; 56: 5387-5396 [PMID: 22869577 DOI: 10.1128/AAC.01186-12].
234. Liverton NJ, Carroll SS, Dimuzio J, Fandozzi C, Graham DJ, Hazuda D, Holloway MK, Ludmerer SW, McCauley JA, McIntyre CJ, Olsen DB, Rudd MT, Stahlhut M, Vacca JP. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob Agents Chemother 2010; 54: 305-311 [PMID: 19841155 DOI: 10.1128/AAC.00677-09].
235. Reesink HW, Fanning GC, Farha KA, Weegink C, Van Vliet A, Van 't Klooster G, Lenz O, Aharchi F, Mariën K, Van Remoortere P, de Kock H, Broeckaert F, Meyvisch P, Van Beirendonck E, Simmen K, Verloes R. Rapid HCV-RNA decline with once daily TMC435: A phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 2010; 138: 913-921 [PMID: 19852962 DOI: 10.1053/j.gastro.2009.10.033].
236. Moreno C, Berg T, Tanwandee T, Thongsawat S, Van Vlierberghe H, Zeuzem S, Lenz O, Peeters M, Sekar V, De Smedt G. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol 2012; 56: 1247-1253 [PMID: 22326470 DOI: 10.1016/j.jhep.2011.12.033].
237. Lenz O, Verbinnen T, Lin TI, Vijgen L, Cummings MD, Lindberg J, Berke JM, Dehertogh P, Fransen E, Scholliers A, Vermeiren K, Ivens T, Raboisson P, Edlund M, Storm S, Vrang L, de Kock H, Fanning GC, Simmen KA. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010; 54: 1878-1887 [PMID: 20176898 DOI: 10.1128/AAC.01452-09].
238. Dvory-Sobol H, Wong KA, Ku KS, Bae A, Lawitz EJ, Pang PS, Harris J, Miller MD, Mo H. Characterization of resistance to the protease inhibitor GS-9451 in hepatitis C virusinfected patients. Antimicrob Agents Chemother 2012; 56: 5289-5295 [PMID: 22869562 DOI: 10.1128/AAC.00780-12].
239. Lagacé L, White PW, Bousquet C, Dansereau N, Dô F, Llinas- Brunet M, Marquis M, Massariol MJ, Maurice R, Spickler C, Thibeault D, Triki I, Zhao S, Kukolj G. In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335. Antimicrob Agents Chemother 2012; 56: 569-572 [PMID: 22024816 DOI: 10.1128/AAC.05166-11].
240. Trozzi C, Bartholomew L, Ceccacci A, Biasiol G, Pacini L, Altamura S, Narjes F, Muraglia E, Paonessa G, Koch U, De Francesco R, Steinkuhler C, Migliaccio G. In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J Virol 2003; 77: 3669-3679 [PMID: 12610142].
241. Koch U, Narjes F. Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. Curr Top Med Chem 2007; 7: 1302-1329 [PMID: 17627559].
242. Holler TP, Parkinson T, Pryde DC. Targeting the non-structural proteins of hepatitis C virus: beyond hepatitis C virus protease and polymerase. Expert Opin Drug Discov 2009; 4: 293-314 [PMID: 23489127 DOI: 10.1517/17460440902762802].
243. Pawlotsky JM, Najera I, Jacobson I. Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase. Antivir Ther 2012; 17: 411-423 [PMID: 22402762 DOI: 10.3851/IMP2088].
244. Pockros PJ, Jensen D, Tsai N, Taylor R, Ramji A, Cooper C, Dickson R, Tice A, Kulkarni R, Vierling JM, Lou Munson M, Chen YC, Najera I, Thommes J. JUMP-C: A randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients. Hepatology 2013; 58: 514-523 [PMID: 23359491 DOI: 10.1002/hep.26275].
245. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887 [PMID: 23607594 DOI: 10.1056/NEJMoa1214853].
246. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44 [PMID: 23281974 DOI: 10.1056/NEJMoa1208953].
247. Tong X, Le Pogam S, Li L, Haines K, Piso K, Baronas V, Yan JM, So SS, Klumpp K, Nájera I. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers lowlevel resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J Infect Dis 2014; 209: 668-675 [PMID: 24154738 DOI: 10.1093/infdis/jit562].
248. Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, Layden TJ, Uprichard SL, Perelson AS. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus halflife. Proc Natl Acad Sci USA 2013; 110: 3991-3996 [PMID: 23431163 DOI: 10.1073/pnas.1203110110].
249. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O'Boyle DR, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96-100 [PMID: 20410884 DOI: 10.1038/nature08960].
250. Pawlotsky JM. New antiviral agents for hepatitis C. F1000 Biol Rep 2012; 4: 5 [PMID: 22403588 DOI: 10.3410/B4-5].
251. Asselah T. NS5A inhibitors: A new breakthrough for the treatment of chronic hepatitis C. J Hepatol 2011; 54: 1069-1072 [PMID: 21167889 DOI: 10.1016/j.jhep.2010.11.033].
252. Conte I, Giuliano C, Ercolani C, Narjes F, Koch U, Rowley M, Altamura S, De Francesco R, Neddermann P, Migliaccio G, Stansfield I. Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture. Bioorg Med Chem Lett 2009; 19: 1779-1783 [PMID: 19216075 DOI: 10.1016/j.bmcl.2009.01.066].
253. Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012; 32 Suppl 1: 88-102 [PMID: 22212578 DOI: 10.1111/j.1478-3231.2011.02699.x].
254. Fridell RA, Wang C, Sun JH, O'Boyle DR, Nower P, Valera L, Qiu D, Roberts S, Huang X, Kienzle B, Bifano M, Nettles RE, Gao M. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 2011; 54: 1924-1935 [PMID: 21809362 DOI: 10.1002/hep.24594].
255. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV directacting antiviral agents: The best interferon-free combinations. Liver Int 2014; 34 Suppl 1: 69-78 [PMID: 24373081 DOI: 10.1111/liv.12423].
256. Ferenci P. Treatment of chronic hepatitis C- Are interferons really necessary? Liver Int 2012; 32 Suppl 1: 108-112 [PMID: 22212580 DOI: 10.1111/j.1478-3231.2011.02705.x].